BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12446919)

  • 1. Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid.
    Erkiliç S; Aydin A; Koçer NE
    Endocr Pathol; 2002; 13(3):207-11. PubMed ID: 12446919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China.
    Song Q; Wang D; Lou Y; Li C; Fang C; He X; Li J
    Diagn Pathol; 2011 Dec; 6():126. PubMed ID: 22188859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
    Nasser SM; Pitman MB; Pilch BZ; Faquin WC
    Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
    Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility.
    Baloch ZW; Abraham S; Roberts S; LiVolsi VA
    Hum Pathol; 1999 Oct; 30(10):1166-71. PubMed ID: 10534163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of cytokeratin 19 in the diagnosis of thyroid papillary carcinoma by quantitative polymerase chain reaction.
    Flanagan JN; Pineda P; Knapp PE; De Las Morenas A; Lee SL; Braverman LE
    Endocr Pract; 2008 Mar; 14(2):168-74. PubMed ID: 18308654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions.
    Palo S; Biligi DS
    Malays J Pathol; 2017 Apr; 39(1):55-67. PubMed ID: 28413206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma.
    Bose D; Das RN; Chatterjee U; Banerjee U
    Indian J Med Paediatr Oncol; 2012 Apr; 33(2):107-11. PubMed ID: 22988353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma.
    Cameron BR; Berean KW
    J Otolaryngol; 2003 Oct; 32(5):319-22. PubMed ID: 14974863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cytokeratin 19 in the differential diagnosis of true papillary carcinoma of thyroid and papillary carcinoma-like changes in Graves' disease.
    Erkiliç S; Koçer NE
    Endocr Pathol; 2005; 16(1):63-6. PubMed ID: 16000848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].
    Yang QX; Shao CK; Feng ZY; Huang BQ; Han AJ; Xiong M; Zhao WL; Wu TT
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):678-81. PubMed ID: 15958307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical diagnosis of papillary thyroid carcinoma.
    Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
    Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
    Tong J; Wang Y; Da JP
    Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
    Abouhashem NS; Talaat SM
    Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
    He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
    Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
    Murtezaoglu AR; Gucer H
    Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules.
    Beesley MF; McLaren KM
    Histopathology; 2002 Sep; 41(3):236-43. PubMed ID: 12207785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA repair proteins may differentiate papillary thyroid cancer from chronic lymphocytic thyroiditis and nodular colloidal goiter.
    Evren B; Yılmaz S; Karadağ N; Sertkaya AÇ; Topaloğlu Ö; Kılınç F
    Sci Rep; 2021 May; 11(1):9932. PubMed ID: 33976347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions.
    Erdogan-Durmus S; Ozcan D; Yarikkaya E; Kurt A; Arslan A
    J Res Med Sci; 2016; 21():49. PubMed ID: 27904595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications.
    Omar E; Madhavan M; Othman NH
    Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.